Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT00822835 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy subjects.

NCT ID: NCT00822484 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy Japanese male subjects.

NCT ID: NCT00820521 Withdrawn - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of GAP-134

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of GAP-134 in healthy subjects, to provide the initial pharmacokinetic profile of the oral formulation of GAP-134 in healthy subjects, and to evaluate the effect on the pharmacokinetic profile of a high-fat meal of 450 mg of GAP-134 administered to healthy subjects.

NCT ID: NCT00820404 Completed - Healthy Subjects Clinical Trials

Study Evaluating Single Doses of BLI-489 in Healthy Subjects

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.

NCT ID: NCT00818129 Completed - Healthy Subjects Clinical Trials

Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to investigate the safety and tolerability of single and multiple oral doses of AZD7295 in healthy male Japanese subjects. This will be done by comparing the effect of AZD7295 to placebo. The study will aslo investigate the absorption, distribution and disappearance of AZD7295 in the body.

NCT ID: NCT00814060 Completed - Healthy Subjects Clinical Trials

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.

NCT ID: NCT00795730 Completed - Alzheimer Disease Clinical Trials

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease

NCT ID: NCT00785460 Completed - Healthy Subjects Clinical Trials

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.

NCT ID: NCT00783341 Completed - Healthy Subjects Clinical Trials

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Start date: November 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.

NCT ID: NCT00780286 Completed - Healthy Subjects Clinical Trials

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy Study 2

Start date: October 2008
Phase: Phase 1
Study type: Interventional

Single usage, open label study in up to 40 adult healthy males. Eligible subjects will receive a single usage of the investigational or commercial device. Retention of the radiolabeled device will be monitored using gamma scintigraphy.